top of page
Nelson Advisors > HealthTech & MedTech Thought Leadership


This Week in European HealthTech and MedTech: 3rd January 2026
European HealthTech this week is characterised by EU‑level AI and data initiatives moving into implementation, fresh and upcoming funding calls for digital health innovators, and a continued tilt toward AI‑driven automation and consolidation plays as 2026 opens. European MedTech this week is shaped by three themes: MDR/IVDR simplification and EUDAMED timing, new guidance for Notified Bodies, and a steady drumbeat of innovation and capital around robotics, neuro and data‑rich
4 days ago4 min read


Nelson Advisors 2026 Video of Market Predictions, Insights and Observations in HealthTech, MedTech and Digital Health
Nelson Advisors 2026 Video of Market Predictions, Insights and Observations in HealthTech, MedTech and Digital Health.
Dec 31, 20251 min read


The "Series A Off-Ramp" defining the European HealthTech landscape for the foreseeable future
For a generation of startups that raised Seed and Series A capital during the boom years, the path forward has bifurcated. The traditional "escalator" model of venture capital, where a Series A round leads predictably to a Series B growth round, followed by Series C scaling and an IPO, has broken down for the vast majority of market participants. In its place, a new phenomenon has emerged: the Series A Off-Ramp.
Dec 24, 202515 min read


This Week in European HealthTech and MedTech: 19th December 2025
The biggest European MedTech developments this week centre on the EU’s proposed overhaul of MDR/IVDR, a broader Commission health package to boost innovation and resilience, and continued capital formation for MedTech and digital health scale‑ups.
Together these moves signal a more innovation‑friendly regulatory path and fresh growth funding for European MedTech heading into 2026.
Dec 19, 20255 min read


European HealthTech and MedTech M&A Predictions for 2026
The European HealthTech and MedTech M&A landscape in 2026 is poised for significant strategic acceleration, marking a transition from cautious, volume-driven dealmaking to high-value, transformative transactions. Deal flow is consolidating toward fewer but substantially larger deals, with market participants prioritising scalable technologies with robust clinical validation and AI integration capabilities.
Dec 2, 20258 min read


This Week in European HealthTech and MedTech: 28th November 2025
Updates for the week of November 24–28, 2025, are headlined by a major intervention from WHO Europe on AI safety, fresh capital for Nordic oncology innovation, and significant new regulatory guidance from the UK's MHRA. Updates from the week of November 24–28, 2025, highlight a significant shift in the regulatory landscape for European MedTech, alongside major investment news and post-conference analysis from MEDICA 2025.
Nov 28, 20255 min read


Who are the leading M&A Advisors for European HealthTech and MedTech Founders?
In terms of volume and relevance to the mid-market founder, the demographic most prevalent in the European innovation ecosystem, firms like Rothschild & Co, Houlihan Lokey and highly specialised boutiques like Nelson Advisors, Arma Partners and Clipperton have emerged as the primary engines of liquidity.
Nov 26, 202513 min read


This Week in European HealthTech and MedTech: 21st November 2025
Key developments in the European MedTech sector for the week of November 21st 2025, have been dominated by major regulatory shifts regarding AI, significant capital injections, and activity surrounding two major industry conferences. While the broader medical device sector is focused on hardware delays, the HealthTech conversation this week shifted sharply toward data access and AI liability.
Nov 23, 20255 min read


Strategic Deployment in European HealthTech: Private Equity Roll Up Strategies in Forgotten Mid Tier Opportunities
The current European HealthTech and MedTech landscape presents a compelling and timely opportunity for specialised Private Equity (PE) deployment, driven by a simultaneous market correction and entrenched structural fragmentation.
Following the "exuberance" and peak valuations of the COVID-19-driven Venture Capital (VC) boom of 2021–2022, a significant shift in investor sentiment has occurred. High interest rates and inflation have elevated the cost of capital, forcing in
Oct 26, 202515 min read


This Week in European HealthTech and MedTech: 17th October 2025
Major developments in European HealthTech this week have been dominated by major funding rounds in biotech, significant regulatory alignment and continued investment in digital health. The last week in European MedTech has been dominated by regulatory and funding activities, as well as continued momentum in digital health and surgical innovation.
Oct 17, 20254 min read


This Week in European HealthTech and MedTech: 5th October 2025
The major stories in the world of European MedTech this week are dominated by regulatory activity under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), a significant European Commission "Call for Evidence" for future reforms, and fresh funding for companies focused on connected and remote monitoring devices.
Oct 5, 20255 min read
bottom of page